Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Impact of disease state on arrhythmic event detection by action potential modelling in cardiac safety pharmacology.

Christophe B, Crumb WJ Jr.

J Pharmacol Toxicol Methods. 2019 Mar - Apr;96:15-26. doi: 10.1016/j.vascn.2018.12.004. Epub 2018 Dec 21.

PMID:
30580044
2.

Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative.

Li Z, Ridder BJ, Han X, Wu WW, Sheng J, Tran PN, Wu M, Randolph A, Johnstone RH, Mirams GR, Kuryshev Y, Kramer J, Wu C, Crumb WJ Jr, Strauss DG.

Clin Pharmacol Ther. 2019 Feb;105(2):466-475. doi: 10.1002/cpt.1184. Epub 2018 Aug 27.

3.

Nonclinical Profile of BLZ-100, a Tumor-Targeting Fluorescent Imaging Agent.

Parrish-Novak J, Byrnes-Blake K, Lalayeva N, Burleson S, Fidel J, Gilmore R, Gayheart-Walsten P, Bricker GA, Crumb WJ Jr, Tarlo KS, Hansen S, Wiss V, Malta E, Dernell WS, Olson JM, Miller DM.

Int J Toxicol. 2017 Mar/Apr;36(2):104-112. doi: 10.1177/1091581817697685. Epub 2017 Mar 17.

4.

Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias.

Blinova K, Stohlman J, Vicente J, Chan D, Johannesen L, Hortigon-Vinagre MP, Zamora V, Smith G, Crumb WJ, Pang L, Lyn-Cook B, Ross J, Brock M, Chvatal S, Millard D, Galeotti L, Stockbridge N, Strauss DG.

Toxicol Sci. 2017 Jan;155(1):234-247. doi: 10.1093/toxsci/kfw200. Epub 2016 Oct 3.

5.

An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel.

Crumb WJ Jr, Vicente J, Johannesen L, Strauss DG.

J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:251-62. doi: 10.1016/j.vascn.2016.03.009. Epub 2016 Apr 6.

PMID:
27060526
6.

Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.

Johannesen L, Vicente J, Mason JW, Erato C, Sanabria C, Waite-Labott K, Hong M, Lin J, Guo P, Mutlib A, Wang J, Crumb WJ, Blinova K, Chan D, Stohlman J, Florian J, Ugander M, Stockbridge N, Strauss DG.

Clin Pharmacol Ther. 2016 Feb;99(2):214-23. doi: 10.1002/cpt.205. Epub 2015 Nov 28.

7.

Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil.

Vicente J, Johannesen L, Mason JW, Crumb WJ, Pueyo E, Stockbridge N, Strauss DG.

J Am Heart Assoc. 2015 Apr 13;4(4). pii: e001615. doi: 10.1161/JAHA.114.001615.

8.

Oxytocin does not directly alter cardiac repolarization in rabbit or human cardiac myocytes.

Qu Y, Fang M, Gao B, Amagasu S, Crumb WJ, Vargas HM.

Pharmacol Res Perspect. 2015 Feb;3(1):e00102. doi: 10.1002/prp2.102. Epub 2014 Dec 9.

9.

Allosteric effects of erythromycin pretreatment on thioridazine block of hERG potassium channels.

Crumb WJ Jr.

Br J Pharmacol. 2014 Apr;171(7):1668-75. doi: 10.1111/bph.12575.

10.

The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate.

Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, Pan S, Gray NS, Hinterding K, Cooke NG, Groenewegen A, Vitaliti A, Sing T, Luttringer O, Yang J, Gardin A, Wang N, Crumb WJ Jr, Saltzman M, Rosenberg M, Wallström E.

Br J Pharmacol. 2012 Nov;167(5):1035-47. doi: 10.1111/j.1476-5381.2012.02061.x.

11.

Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis.

Crumb WJ Jr, Ekins S, Sarazan RD, Wikel JH, Wrighton SA, Carlson C, Beasley CM Jr.

Pharm Res. 2006 Jun;23(6):1133-43. Epub 2006 May 25.

PMID:
16715368
12.

Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil.

Dustan Sarazan R, Crumb WJ Jr, Beasley CM Jr, Emmick JT, Ferguson KM, Strnat CA, Sausen PJ.

Eur J Pharmacol. 2004 Oct 19;502(3):163-7.

PMID:
15476742
13.

Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels.

Chiu PJ, Marcoe KF, Bounds SE, Lin CH, Feng JJ, Lin A, Cheng FC, Crumb WJ, Mitchell R.

J Pharmacol Sci. 2004 Jul;95(3):311-9.

14.

Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel.

Stanat SJ, Carlton CG, Crumb WJ Jr, Agrawal KC, Clarkson CW.

Mol Cell Biochem. 2003 Dec;254(1-2):1-7.

PMID:
14674677
15.

Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk.

Lacroix P, Crumb WJ, Durando L, Ciottoli GB.

Eur J Pharmacol. 2003 Sep 5;477(1):69-72.

PMID:
14512100
16.

Patch-clamp studies of human cardiac ion channels in the evaluation of cardiac electrophysiological effects of compounds.

Crumb WJ, Cavero I.

Curr Protoc Pharmacol. 2003 May;Chapter 10:Unit10.8. doi: 10.1002/0471141755.ph1008s20.

PMID:
21956800
17.

Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel.

Ekins S, Crumb WJ, Sarazan RD, Wikel JH, Wrighton SA.

J Pharmacol Exp Ther. 2002 May;301(2):427-34.

PMID:
11961040
18.

Effects of cocaine and its major metabolites on the HERG-encoded potassium channel.

Ferreira S, Crumb WJ Jr, Carlton CG, Clarkson CW.

J Pharmacol Exp Ther. 2001 Oct;299(1):220-6.

PMID:
11561083
19.
20.
21.

Fatty acid block of the transient outward current in adult human atrium.

Crumb WJ Jr, Munfakh N, Heck HA, Harrison LH Jr.

J Pharmacol Exp Ther. 1999 Apr;289(1):386-91.

PMID:
10087028
22.

Quinidine interactions with human atrial potassium channels: developmental aspects.

Nenov NI, Crumb WJ Jr, Pigott JD, Harrison LH Jr, Clarkson CW.

Circ Res. 1998 Dec 14-28;83(12):1224-31.

PMID:
9851939
23.

Stable expression and characterization of the human brain potassium channel Kv2.1: blockade by antipsychotic agents.

Wible B, Murawsky MK, Crumb WJ Jr, Rampe D.

Brain Res. 1997 Jun 27;761(1):42-50.

PMID:
9247064
24.
25.

Description of a nonselective cation current in human atrium.

Crumb WJ Jr, Pigott JD, Clarkson CW.

Circ Res. 1995 Nov;77(5):950-6.

PMID:
7554149
26.

The pH dependence of cocaine interaction with cardiac sodium channels.

Crumb WJ Jr, Clarkson CW.

J Pharmacol Exp Ther. 1995 Sep;274(3):1228-37.

PMID:
7562493
27.

Comparison of Ito in young and adult human atrial myocytes: evidence for developmental changes.

Crumb WJ Jr, Pigott JD, Clarkson CW.

Am J Physiol. 1995 Mar;268(3 Pt 2):H1335-42.

PMID:
7900886
28.
29.

Cocaethylene, a metabolite of cocaine and ethanol, is a potent blocker of cardiac sodium channels.

Xu YQ, Crumb WJ Jr, Clarkson CW.

J Pharmacol Exp Ther. 1994 Oct;271(1):319-25.

PMID:
7965731
30.

Variability of the QTc interval: impact on defining drug effect and low-frequency cardiac event.

Morganroth J, Brown AM, Critz S, Crumb WJ, Kunze DL, Lacerda AE, Lopez H.

Am J Cardiol. 1993 Aug 26;72(6):26B-31B.

PMID:
8256752
31.
32.

Electrocardiographic evidence for cocaine cardiotoxicity in cat.

Crumb WJ Jr, Kadowitz PJ, Xu YQ, Clarkson CW.

Can J Physiol Pharmacol. 1990 May;68(5):622-5.

PMID:
2340451
33.

Characterization of cocaine-induced block of cardiac sodium channels.

Crumb WJ Jr, Clarkson CW.

Biophys J. 1990 Mar;57(3):589-99.

Supplemental Content

Loading ...
Support Center